• Empowering you with objective information to assess pulmonary nodules.

  • Potentially avoiding biopsy or surgery – a reason to smile.

  • Simultaneously measures multiple proteins associated with lung cancer.

Xpresys Lung

Xpresys Lung is a molecular blood test developed to provide non-invasive, objective information for assessment of pulmonary nodules. When combined with current clinical assessment, Xpresys Lung may be able to help reduce unnecessary invasive procedures. By reducing these, our objectives are to improve patient outcomes, reduce complications, and lessen the cost to the healthcare system.

Learn more

Upcoming Events



American Thoracic Society May 2018
Steven Springmeyer, MD and Alexander Porter, MD will be attending the 114th American Thoracic Society International Conference in San Diego, May 18-23. Indi data will be presented from the PANOPTIC study that further evaluates the clinical validation of Xpresys Lung 2 as recently e-published in CHEST (Silvestri GA, Tanner NT, Kearney P, Vachani A, Massion P, Porter A, Springmeyer SC, Fang KC, Midthun D, Mazzone PJ) for the PANOPTIC Trial Team. Assessment of Plasma Proteomics Biomarker’s Ability to Distinguish Benign from Malignant Lung Nodules: Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) trial.

View all events

About Indi

Indi is creating powerful new tools to help physicians diagnose complex diseases with a non-invasive blood test. By measuring multiple biomarkers that serve as sentinels of disease – we are creating tests that help physicians diagnose disease states with greater accuracy.

Learn more

Good Work
You are now leaving this website. If you would like to continue, click Continue.
Cancel Continue